Treatment of HIV infection.
Indicated for use as a NNRTI agent as part of a 3-drug combination regimen.
Monitor viral load prior to initiation or modification of treatment.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.
Monitor hepatitis B screening.
Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.
Common
Serious
Multiple drug-drug interactions
Antimicrobial class: Antiretroviral agent, Non-nucleoside reverse transcriptase inhibitor
Pregnancy category: D
Average serum half life: 40-55 hours
Urine penetration: Therapeutic
CSF penetration: Therapeutic
Precautions: Monotherapy should not be used as viral cross-resistance may develop if used alone or added as a sole agent to a failing regimen.
Liver function monitoring recommended for all patients.
Not recommended in patients with moderate to severe hepatic impairment.
Late-onset neurotoxicity may occur months to years after beginning therapy, especially in patients with CYP2B6 genetic polymorphisms associated with increased efavirenz levels; discontinuation may be warranted.
Immediate medical evaluation recommended for serious psychiatric symptoms.
Negative pregnancy test warranted prior to therapy initiation.
항생제
